The high prevalence of undiagnosed prostate cancer at autopsy: Implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era

International Journal of Cancer

Volumn 137, Issue 12, 2015, Pages 2795-2802

  Jahn, Jaquelyn L ^a,b   Giovannucci, Edward L ^a,b   Stampfer, Meir J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

autopsy; epidemiology; lethal prostate cancer; prostate cancer; PSA screening

Indexed keywords

FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

AFRICAN AMERICAN; AUTOPSY; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CAUCASIAN; EPIDEMIOLOGICAL DATA; FOLLOW UP; HUMAN; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; ASYMPTOMATIC DISEASES; BLOOD; EARLY CANCER DIAGNOSIS; MALE; MASS SCREENING; PROSTATIC NEOPLASMS;

ASYMPTOMATIC DISEASES; AUTOPSY; EARLY DETECTION OF CANCER; HUMANS; MALE; MASS SCREENING; PREVALENCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84943661719     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29408     Document Type: Review

References (59)

1. Mariotto AB, Etzioni R, Krapcho M, Feuer EJ,. Reconstructing PSA testing patterns between black and white men in the US from medicare claims and the national health interview survey. Cancer 2007; 109: 1877-86
2. Draisma G, Etzioni R, Tsodikov A, et al., Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009; 101: 374-83
3. Draisma G, Boer R, Otto SJ, et al., Lead times and overdetection due to prostate-specific antigen screening: estimates from the european randomized study of screening for prostate cancer. J Natl Cancer Inst 2003; 95: 868-78
4. Auvinen A, Määttänen L, Stenman U-H, et al., Lead-time in prostate cancer screening (finland). Cancer Causes Control 2002; 13: 279-85
5. Finne P, Fallah M, Hakama M, et al., Lead-time in the european randomised study of screening for prostate cancer. Eur J Cancer 2010; 46: 3102-8
6. Loeb S, Bjurlin M, Nicholson J, et al., Overdiagnosis and Overtreatment of Prostate Cancer. Eur Urol 2014; 65: 1046-55
7. Carter HB,. American urological association (AUA) guideline on prostate cancer detection: process and rationale. BJU Int 2013; 112: 543-7
8. Qaseem A, Barry MJ, Denberg TD, et al., Screening for prostate cancer: a guidance statement from the clinical guidelines committee of the american college of physicians. Ann Intern Med 2013; 158: 761-9
9. Moyer VA,. Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2012; 157: 120-34
10. Haas GP, Delongchamps N, Brawley OW, et al., The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol 2008; 15: 3866-71
11. Moore RA,. The morphology of small prostatic carcinoma. J Urol 1935; 33: 224-34
12. Andrews GS., Latent Carcinoma of the Prostate. J Clin Pathol 1949; 2: 197-208
13. Edwards CN, Steinthorsson E, Nicholson D,. An autopsy study of latent prostatic cancer. Cancer 1953; 6: 531-54
14. Franks LM,. Latent carcinoma of the prostate. J Pathol Bacteriol 1954; 68: 603-16
15. Halpert B, Schmalhorst WR,. Carcinoma of the prostate in patients 70 to 79 years old. Cancer 1966; 19: 695-8
16. Lundberg S, Berge T,. Prostatic carcinoma: an autopsy study. Scand J Urol Nephrol 1970; 4: 93-7
17. Breslow N, Sternby NH, Tulinius H, et al., Latent carcinoma of prostate at autopsy in seven areas. The international agency for research on cancer, lyons, france. Int J Cancer 1977; 20: 680 [PMC ][924691]
18. Guileyardo JM, Johnson WD, Welsh RA, et al., Prevalence of latent prostate carcinoma in two U.S. populations. J Natl Cancer Inst 1980; 65: 311-6
19. Holund B,. Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol 1980; 14: 29-35
20. Stemmermann GN, Nomura AM, Chyou PH, Yatani R,. A prospective comparison of prostate cancer at autopsy and as a clinical event: the hawaii japanese experience. Cancer Epidemiol Biomark Prev 1992; 1: 189
21. Sakr WA, Haas GP, Cassin BF, et al., The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993; 150: 379-85
22. Sánchez-Chapado M, Olmedilla G, Cabeza M, et al., Prevalence of prostate cancer and prostatic intraepithelial neoplasia in caucasian mediterranean males: an autopsy study. The Prostate 2003; 54: 238-47
23. Soos G, Tsakiris I, Szanto J, et al., The prevalence of prostate carcinoma and its precursor in hungary: an autopsy study. Eur Urol 2005; 48: 739-44
24. Stamatiou K, Alevizos A, Perimeni D, et al., Frequency of impalpable prostate adenocarcinoma and precancerous conditions in greek male population: an autopsy study. Prostate Cancer Prostatic Dis 2006; 9: 45-9
25. Powell IJ, Bock CH, Ruterbusch JJ, Sakr W,. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white american men, and influences racial progression and mortality disparity. J Urol 2010; 183: 1792-6
26. Zlotta AR, Aldaoud N, Fleshner N, et al., Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened caucasian and asian men. J Natl Cancer Inst 2013; 105: 1050
27. Lee YS, Shanmugaratnam K,. Latent prostate carcinoma in singapore chinese. Singapore Med J 1972; 13: 1-6
28. Akazaki K, Stemmerman GN,. Comparative study of latent carcinoma of the prostate among japanese in japan and hawaii. J Natl Cancer Inst 1973; 50: 1137-44
29. Gu FL, Xia TL, Kong XT,. Preliminary study of the frequency of benign prostatic hyperplasia and prostatic cancer in china. Urology 1994; 44: 688-91
30. Yatani R, Shiraishi T, Nakakuki K, et al., Trends in frequency of latent prostate carcinoma in japan from 1965-1979 to 1982-1986. J Natl Cancer Inst 1988; 80: 683-7
31. Society AC, Cancer Treatment and Survivorship Facts & Figures 2014-2015. Am Cancer Soc 2014
32. Ferlay J, Shin HR, Bray F, et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917
33. Fundamentals of treatment: Undiagnosed: Prostate Oncology Specialists, 2014. Available at: http://www.prostateoncology.com/education/fundamentals-of-treatment/undiagnosed
34. Thompson IM, Lippman SM, Carlin SM, et al., The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-24
35. Hoffman KE, Niu J, Shen Y, et al., Physician Variation in Management of Low-Risk Prostate Cancer: A Population-Based Cohort Study. JAMA Intern Med 2014; 174: 1450-9
36. Giovannucci E, Liu Y, Platz EA, et al., Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 2007; 121: 1571-8
37. Wilson KM, Kasperzyk JL, Rider JR, et al., Coffee consumption and prostate cancer risk and progression in the health professionals Follow-up study. J Natl Cancer Inst 2011; 103: 876-84
38. Zu K, Mucci L, Rosner BA, et al., Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. J Natl Cancer Inst 2014; 106: djt430
39. Augustsson K, Michaud D, Rimm E, et al., A prospective study of intake of fish and marine fatty acids and prostate cancer. Cancer Epidemiol Biomark Prev 2003; 12: 64
40. Giovannucci EL, Liu Y, Leitzmann MF, et al., A prospective study of physical activity and incident and fatal prostate cancer. Arch Intern Med 2005; 165: 1005-10
41. Platz EA, Leitzmann MF, Visvanathan K, et al., Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98: 1819-25
42. Discacciati A, Orsini N, Wolk A,. Body mass index and incidence of localized and advanced prostate cancer-a dose-response meta-analysis of prospective studies. Ann Oncol 2012; 23: 1665-71
43. Szymanski KM, Wheeler DC, Mucci LA,. Fish consumption and prostate cancer risk: a review and meta-analysis. Am J Clin Nutr 2010; 92: 1223-33
44. Huncharek M, Haddock KS, Reid R, Kupelnick B,. Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies. Am J Public Health 2010; 100: 693-701
45. Li J, Djenaba JA, Soman A, et al., Recent trends in prostate cancer incidence by age, cancer stage, and grade, the united states, 2001-2007. Prostate Cancer 2012; 2012: 691380-8
46. Andren O, Fall K, Franzen L, et al., How well does the gleason score predict prostate cancer death? a 20-year followup of a population based cohort in sweden. J Urol 2006; 175: 1337-40
47. Stark JR, Loda M, Giovannucci EL, et al., Gleason score and lethal prostate cancer: does 3+4=4+3?. J Clin Oncol Off J Am Soc Clin Oncol 2009; 27: 3459-64
48. Bianco JFJ, Scardino PT, Eastham JA,. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). Urology 2005; 66: 83-94
49. Brasky TM, Parnes HL, Klein EA, et al., Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst 2013; 105: 1132
50. Szymanski KM, Wheeler DC, Mucci LA,. Fish consumption and prostate cancer risk: a review and meta-analysis. Am J Clin Nutr 2010; 92: 1223-33
51. Chavarro JE, Stampfer MJ, Hall MN, et al., A 22-y prospective study of fish intake in relation to prostate cancer incidence and mortality. Am J Clin Nutr 2008; 88: 1297
52. Schroder FH, Hugosson J, Roobol MJ, et al., Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014; 384: 2027-35
53. Bill-Axelson A, Spångberg A, Andrén O, et al., Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014; 370: 932
54. Lippman SM, Hartline JA, Parsons JK, et al., Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT). JAMA: J Am Med Assoc 2009; 301: 39-51
55. Pinsky PF, Black A, Parnes HL, et al., Prostate cancer specific survival in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Cancer Epidemiol 2012; 36: e401-e6
56. Stampfer MJ, Jahn JL, P HG,. Further evidence that prostate-specific antigen screening reduces prostate cancer mortality. J Natl Cancer Inst 2014; 106: dju026
57. Carlsson S, Vickers AJ, Roobol M, et al., Prostate cancer screening: facts, statistics, and interpretation in response to the US preventive services task force review. J Clin Oncol 2012; 30: 2581-4
58. Hugosson J, Carlsson S, Aus G, et al., Mortality results from the goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725-32
59. Nimptsch K, Kenfield S, Jensen MK, et al., Dietary glycemic index, glycemic load, insulin index, fiber and whole-grain intake in relation to risk of prostate cancer. Cancer Causes Control 2011; 22: 51-61